Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
Andrés F. Cardona, Daniel Jaramillo-Velásquez, Alejandro Ruíz-Patiño, Carolina Polo, Enrique Jiménez, Fernando Hakim, Diego Gómez, Juan Fernando Ramón, Hernando Cifuentes, Juan Armando Mejía, Fernando Salguero, Camila Ordóñez‐Reyes, Álvaro Muñoz, Sonia Bermúdez, Nicolás Useche, Diego Pineda, Luisa Ricaurte, Zyanya Lucía Zatarain-Barrón, July Rodríguez, Jenny Ávila, Leonardo Rojas, Elvira Jaller, Carolina Sotelo, Juan Esteban García-Robledo, Nicolás Santoyo, Christian Rolfo, Rafael Rosell, Óscar Arrieta
Topics & Concepts
BevacizumabOsimertinibMedicineTemozolomideInternal medicineOncologyLung cancerProgression-free survivalEpidermal growth factor receptorErlotinibGastroenterologyCancerChemotherapyGlioma Diagnosis and TreatmentRadiomics and Machine Learning in Medical ImagingBrain Metastases and Treatment